Helius Medical Technologies Announces a Strategic Reverse Split
Helius Medical Technologies, Inc. (Nasdaq:HSDT) is making waves in the world of neurotechnology with the announcement of a 1-for-50 reverse split of its Class A common stock. This significant decision was made to bolster its market standing and to align with the listing requirements of the Nasdaq Capital Market.
The Details of the Reverse Stock Split
The reverse stock split is set to take effect at 5:00 pm Eastern time on June 30, 2025, aiming to enhance the trading conditions for its common stock. After this date, the company’s shares will be traded on a split-adjusted basis starting July 1, 2025.
Stockholder Approval
This strategic move came after a special meeting where stockholders expressed their support. Initially, they sanctioned a potential range for the reverse split ratio from 1-for-2 to 1-for-250. Ultimately, the Board of Directors opted for an effective split ratio of 1-for-50, which translates into a scenario where every 50 shares held by investors will be consolidated into one.
Understanding the Impact
The reverse split will not affect the par value of the shares, which remains at $0.001, nor the overall authorized number of shares, which stands at 150 million. However, the outstanding shares will dwindle from approximately 33.8 million to around 0.7 million.
Financial Implications of the Split
With the implementation of this reverse split, there will be an automatic reduction in the number of shares outstanding, which will also affect stock options and warrants proportionately. It is crucial for investors to understand that any fractional shares resulting from this initiative will be rounded down, with shareholders receiving cash equivalent to the market value of those fractions based on the company's closing stock price.
Ongoing Commitment to Shareholders
Helius Medical Technologies remains dedicated to fostering shareholder value and maintaining transparency throughout this process. Investors can look forward to further details as the company continues to operate under the Nasdaq symbol “HSDT.”
Looking Ahead
The implications of this reverse split extend beyond immediate financial adjustments. As Helius Medical Technologies advances its mission in the neurotech realm, it is also on a clear path to meet its obligations to the Nasdaq. The adjustments and strategic decisions being made now will help position the company for future success in delivering innovative solutions for patients with neurologic conditions.
About Helius Medical Technologies
Helius Medical Technologies is at the forefront of innovation in the medical device sector, specializing in the treatment of neurologic deficits. Their pioneering Portable Neuromodulation Stimulator (PoNS) is a testament to their commitment to enhancing the quality of life for individuals dealing with neurologic diseases. For more insight into their groundbreaking approaches and products, potential investors and interested parties can explore their website.
Contact Information
For inquiries and further information regarding Helius Medical Technologies, reach out to:
Philip Trip Taylor
Gilmartin Group
investorrelations@heliusmedical.com
Frequently Asked Questions
What is the purpose of the reverse stock split announced by Helius Medical Technologies?
The reverse stock split aims to enhance the company's stock market position and comply with Nasdaq listing requirements.
When will the reverse stock split take effect?
The reverse stock split will be effective from June 30, 2025, with shares trading on a split-adjusted basis starting July 1, 2025.
How will the reverse stock split affect current shareholders?
Shareholders will see their shares consolidated as 50 existing shares will become one new share, but the par value remains unchanged.
What will happen to fractional shares after the reverse split?
Any fractional shares will be rounded down to the nearest whole share, and shareholders will be compensated with cash for those fractions based on the market value.
How many shares will be outstanding after the split?
The total outstanding shares will decrease from approximately 33.8 million to about 0.7 million following the reverse split.
